The policy cites multiple CPT and proprietary lab codes as examples but makes clear that inclusion or exclusion of any code does not guarantee coverage. Providers should confirm current coding guidance and prior-authorization requirements with the payer before ordering or billing genetic tests.

The policy states that hereditary cancer susceptibility panel targeted mRNA sequencing for interpretation of variants of unknown significance (VUS) is not supported, because such RNA analyses are typically considered quality-assurance or follow-up procedures without proven clinical utility and are not endorsed as routine coverage for VUS resolution.

Across Lynch, APC/MUTYH, and other gene sections the policy notes that mRNA sequencing analyses used solely to interpret VUS are not supported. These RNA-based tests are characterized as QA or follow‑up activities rather than established, medically necessary diagnostic procedures and therefore are not reimbursed as routine clinical testing.

For each gene-specific section the policy makes explicit that testing for the listed genes is supported only for the medically necessary indications enumerated in that section. Any use of these genes outside the specified personal- or family-history, tumor-based, or predictive-model thresholds is not supported by current evidence and therefore not covered.

The policy reiterates that testing for the named genes/syndromes is only supported when the member meets the specific personal, family, tumor, or predictive-model criteria listed. Requests that do not meet those pre-specified criteria (for targeted or sequencing/deletion-duplication analyses) are considered not supported.

The document highlights that ATM and CHEK2 are not high-penetrance breast cancer genes and that absence of gene-specific clinical criteria may limit coverage; standalone sequencing of ATM or CHEK2 without guideline-based clinical indications or supporting family history may therefore be considered not medically necessary.

The policy references ASCO guidance noting it may be appropriate to exclude some polyposis-related genes from panels when a patient's personal or family history is not consistent with those phenotypes, supporting a targeted rather than indiscriminate panel approach when clinical suspicion is limited.

Operational edits removed or replaced certain previously listed panel and vendor/test names from the policy reference table. The policy directs reviewers to the full reference table for specifics and notes that several test-name standardizations and code replacements were applied during the update.

The policy removed prior statements that panels exclude genes without a ClinGen association; this change does not create new explicit test exclusions in the document — rather, it simplifies language and does not add any new blanket exclusions based on ClinGen status.

Each gene-specific section includes an explicit statement that current evidence does not support testing for indications beyond those listed as medically necessary. This means requests must map to the listed clinical, family-history, tumor, or predictive-model criteria to be considered eligible for coverage.

The policy clarifies that targeted variant analyses (family- or tumor-directed) and sequencing/deletion-duplication testing for the named genes are covered only when the member meets the specific listed indications. Indications include a known familial pathogenic/likely pathogenic variant, tumor‑identified P/LP variant with pending germline analysis, syndrome-specific clinical features, or predictive-model thresholds where applicable.

Summarizing evidence limitations, the policy states that testing is not supported outside the enumerated, guideline-aligned indications. Requests that fall outside the documented per-gene or per-panel criteria risk denial because current evidence does not demonstrate clinical utility for those uses.

The document reiterates that ATM and CHEK2 are lower-penetrance genes relative to high-penetrance breast cancer genes; without gene-specific clinical criteria, standalone sequencing of these genes may be unsupported and should not be requested as first-line testing absent qualifying clinical or family-history indications.

The policy references ASCO's position that it can be appropriate to exclude certain polyposis-related genes from multigene panels when the patient's phenotype or family history is not consistent with those conditions, reinforcing a phenotype-driven selection of genes on panels.

The policy notes multiple edits to the policy reference table, including standardizing vendor/test names and replacing or removing specific CPT/HCPCS entries; providers and coding staff should consult the updated reference table and use the revised codes when submitting prior authorization requests or claims.

Several vendor/test names and some previously listed items were removed from the reference table as part of operational simplification. The policy advises reviewers to rely on the current table for the authoritative list of covered tests and associated codes.

The update removed certain standalone background statements and age restrictions where rationale was limited (for example, some minimum-age language was removed for panels). These operational changes broadened eligibility in a few contexts while preserving the requirement that testing meet specified clinical criteria.

Prior explicit statements that panels exclude genes without a ClinGen association were removed from prostate and pancreatic sections; this was an operational clarification and does not introduce new explicit test exclusions in the policy.

The policy clarifies that ClinGen-exclusion statements were removed from prostate and pancreatic sections for ease of use; the change was editorial and does not create new exclusions but simplifies the prior language about panel composition.

The policy includes an implicit denial note: testing that does not meet the clarified, guideline-aligned criteria is not covered. Providers should apply the updated clinical criteria to determine whether a proposed test is medically necessary prior to ordering or seeking authorization.

An operational edit removed the previous minimum-age requirement for pan-cancer panels (the prior '≥18 years' language was removed). As a result, age-based restrictions that lacked clear rationale were eliminated, though all other syndrome- and gene-specific clinical criteria remain applicable.

Background guideline references were updated (for example, NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic updated from v2.2024 to v3.2024) and professional-society guidance (e.g., ASCO/SSO 2024 breast cancer germline testing recommendations) were incorporated into the policy rationale.